News

GS-9674 is an investigational, selective and non-steroidal agonist of the (FXR), which is a nuclear hormone receptor that is highly expressed in the gastrointestinal tract and liver. FXR

It follows the successful completion of milestones set in the initial Phase 1 grant for $223,000, awarded in 2016. Both grants focus on a process known as cellular

VIS649 is a monoclonal antibody targeting the B-cell growth factor APRIL (A Proliferation Inducing Ligand) for the potential treatment of imumuglobulin A nephropathy (IgA nephropathy or IgAN), one

The merger of BioTime and Asterias Biotherapeutics will enable to create a major cell therapy company. As per terms of the deal, Asterias stockholders will secure 0.71 common

The company has randomized the first patient of the mid-stage trial which will assess the efficacy and safety of Blautix in patients having IBS with constipation (IBS-C) and/or

The decision is driven by recent findings derived from a non-interventional human study utilizing a clinically validated CANscript platform. GBR 1342 is based on Glenmark’s proprietary BEAT platform

This name reflects the company’s focus on advancing the science of cytokine-based immunotherapy for the treatment of a range of cancers. Brooklyn ImmunoTherapeutics general partner and board chair

Mirum Pharmaceuticals is focused on the development of an approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions. Maralixibat is under development for

The Switzerland-based Covis Pharma will also make conditional sales-related payments for the three over-the-counter (OTC) drugs of up to $21m over four years from 2019. AstraZeneca global product